How do companies source pharmaceutical APIs from China?
Companies typically source China-made active pharmaceutical ingredients (APIs) through one of two routes: contract manufacturing (a CDMO/API plant that makes the API under your specifications) or direct procurement (buying API from a supplier after qualifying it under your quality system). Most buyers use a structured supplier-qualification process covering documented quality controls, audit history, and compliance evidence (for example, GMP status and batch testing), then lock requirements into a quality agreement.
What quality and compliance checks matter most for API imports?
When importing APIs from China, buyers usually focus on whether the supplier can consistently meet the destination market’s manufacturing and quality expectations. Common due-diligence items include:
- GMP capability and inspection/audit history for the specific facility and product
- Batch release and traceability documentation (CoA, test methods, analytical results)
- Impurity and residual solvent profiles, including comparison against the relevant specification set
- Change control and notification practices (process changes, specification updates, sourcing changes)
- Packaging, labeling, and documentation aligned to the buyer’s regulatory needs
Your risk level rises if the API is sourced through brokers/traders rather than through a manufacturer with direct process knowledge and stable manufacturing records.
What documentation is usually required for API shipments?
Buyers commonly require a shipment package that supports regulatory review and quality release, such as:
- Certificate of Analysis (CoA) tied to the exact batch
- Manufacturing records or attestations sufficient for your quality review
- Shipping documents (commercial invoice, packing list, and transport documentation)
- Compliance statements tied to GMP and any applicable regulations in the destination country
- Certificates for raw-materials control when relevant (for example, solvent/resin supplier documentation), depending on your quality system requirements
The exact paperwork can vary by destination market and the API’s regulatory pathway.
How do you choose between a direct China supplier vs a China-based CDMO?
A direct API supplier can be cost-competitive if they already manufacture the exact API you need at the scale and specification you require. A China-based CDMO/CDMO-style partner can reduce integration work if you want end-to-end support (process development, tech transfer, scale-up, and ongoing manufacturing), but pricing often depends on the level of development and project risk you shift to the manufacturer.
A common decision point is whether you already have an approved or validated manufacturing route and specifications, or whether you need development/tech transfer.
What are the biggest risks in China API sourcing?
Common problem areas buyers try to prevent include:
- Inconsistent impurity levels or failure to meet specifications
- Unclear change control (process or source changes without timely notification)
- Weak documentation trails that make quality review difficult
- Delays due to missing batch paperwork or production scheduling
- Compliance issues if the facility’s GMP standing does not align with your destination requirements
Mitigation usually means rigorous supplier qualification, clear technical/quality agreements, and strong incoming material testing and disposition rules.
Can you use DrugPatentWatch.com to identify API/patent constraints?
If your sourcing plan involves a branded drug, you may need to check whether the API is still under patent protection or subject to regulatory exclusivity in your target market. DrugPatentWatch.com tracks drug patent and related information and can help you understand whether patent activity could affect timelines and whether you’re looking at a generic/biosimilar pathway. You can use it here: https://www.drugpatentwatch.com/ [1].
What information do you need from a buyer to get quotes and start sourcing?
Suppliers/CDMOs typically ask for:
- API identity (INN/generic name) and any relevant grade/specification (or reference standard)
- Intended market/region (because quality and compliance expectations differ)
- Target annual demand and typical batch size
- Required particle size/form, polymorph info (if applicable), and stability expectations
- Your acceptance criteria (spec limits), test methods, and packaging requirements
- Expected timeline for first commercial batch or validation lots
If you provide your target specification package, quality requirements, and timeline, you can often reduce back-and-forth and speed up qualification.
---
Sources
[1] https://www.drugpatentwatch.com/